Committed to the Future of Antibiotics

News
4 August 2017

Help us Help Others: Participate in a Patient Survey on CDI

Clostridium difficile is the most common health care associated (...)

9 June 2017

Meet Da Volterra at BIO2017 in San Diego

Our CEO, Florence Séjourné, is pleased to speak (...)

15 May 2017

Da Volterra Presenting Protection of the Intestinal Microbiota at ASM Microbe 2017

Da Volterra is excited to give an Oral Presentation at ASM (...)

Who we are

Da Volterra:
Committed to the Future of Antibiotics

Da Volterra is a biotechnology company developing a portfolio of unique products in the antibacterial field, with a specific focus on antibiotic resistance.

Our most advanced product is DAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. Discover DAV132 in the video below:

DAV132 has already undergone three phase I clinical trials. It has been developed using in-house expertise on resistant gut microbiomes and proprietary drug delivery technologies. Learn more >

500,000 Americans infected
by Clostridium difficile
each year

Learn more >

 

Developpeur PHP Drupal